102460.Ks
The company operates in the pharmaceuticals industry, focusing on the development, production, and sale of prescription drugs and related healthcare products.
Business. The company operates in the pharmaceuticals industry, focusing on the development, production, and sale of prescription drugs and related healthcare products.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
The company operates in the pharmaceuticals industry, focusing on the development, production, and sale of prescription drugs and related healthcare products.
The company's capital structure is characterized by a debt-to-equity ratio of 0.98, indicating a relatively balanced mix of debt and equity financing. However, the company's liquidity position is constrained, with a current ratio of 0.56, suggesting that it may struggle to meet short-term obligations without additional financing. The company's price-to-book ratio of 0.97 and price-to-tangible-book ratio of 0.97 indicate that the market values the company's equity at a slight discount to its book value.
Profitability metrics reveal a challenging operating environment for the company. The company reported a net loss of 29,633,118,380 KRW, with a return on equity of -13.45% and a return on assets of -6.37%. These figures are significantly below the industry median for profitability, indicating that the company is underperforming relative to its peers in terms of generating returns on invested capital and assets.
The company's revenue is primarily concentrated in a single geographic region, with no disclosed segment breakdown. This lack of diversification increases the company's exposure to regional economic and regulatory risks. The absence of detailed segment data limits the ability to assess the performance of different product lines or geographic markets.
The company's growth trajectory is mixed. While it reported a revenue of 145,928,626,140 KRW, the net loss and negative operating income suggest that the company is not currently generating sustainable earnings. The outlook for the current fiscal year indicates a continuation of this trend, with no significant improvement in revenue or profitability expected in the near term.
Risk factors for the company include its high debt load and negative net cash position, which could limit its ability to invest in growth opportunities or withstand economic downturns. The company's liquidity risk is rated as medium, and its dilution risk is low, indicating that while it may need to raise additional capital, it is not currently facing significant pressure to issue new shares.
Recent events, including the company's latest financial filing, show a continued focus on managing cash flow and reducing debt. The company's operating cash flow of 1,456,689,950 KRW is insufficient to cover its capital expenditures of 7,915,547,610 KRW, leading to a negative free cash flow of 5,754,212,990 KRW. This suggests that the company is investing heavily in its operations but is not generating enough cash to sustain these investments without external financing.
- The company is operating at a net loss with a negative return on equity and assets, indicating poor profitability.
- The company's liquidity position is weak, with a current ratio of 0.56 and a negative net cash position.
- The company's revenue is concentrated in a single geographic region, increasing its exposure to regional risks.
- The company is investing in capital expenditures but is not generating sufficient free cash flow to sustain these investments.
- The company's debt-to-equity ratio is balanced, but its high debt load and negative net cash position pose liquidity risks.
Bull / Bear case
analysis pipelineIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Ev To Operating Cash Flowenterprise_value / operating_cash_flow
- Return On Equitynet_income / total_equity
- Price To Bookmarket_price / (adjusted_book_value / shares_outstanding_diluted)
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Market Priceinput from market-data provider (delayed close or quote-shim mid)
- Market Capmarket_price * shares_outstanding_diluted
- 102460.KS Market data — financials · 2026-05-26
- Reyon Pharmaceutical Co Ltd Market data — analyst estimates · 2026-05-26